Retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptors, has shown even more dramatic weight loss in clinical trials, with some participants losing over 25% of their body weight
Talk about goals and risks with your prescribing clinician to decide
Volume is now expected to decline within the range of 1.4% to 3.4% in 2026, an increase from Big Chalks end-of-year prediction of 1.1% to 3.1%
Both trials suggest maintenance strategies, such as lower-dose injections or oral therapies, could offer patients more flexible, potentially more convenient options for sustaining weight loss after intensive treatment
Dehydration exacerbates nausea and other stomach issues
The gradual onset is actually beneficial because it supports sustainable lifestyle changes rather than rapid or extreme shifts in eating behavior